Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.51 |
| ▸ | XDH | P47989 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15215602 | 0.75 | MPO (0.58) | MPOXDHCA12CA2CA9 | |
| SCHEMBL2730278 | 0.71 | KDM4E (0.65) | MPOXDHKDM4EALDH1A1MEN1 | |
| SCHEMBL2731084 | 0.71 | ALDH1A1 (0.68) | MPOXDHKDM4EALDH1A1MEN1 | |
| SCHEMBL2731359 | 0.70 | KMT2A (0.70) | MPOXDHKDM4EALDH1A1MEN1 | |
| SCHEMBL10288996 | 0.69 | MPO (0.54) | MPOXDHCA12CA2CA9 | |
| SCHEMBL27820478 | 0.68 | KIF11 (0.57) | KDM4EALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL15215601 | 0.68 | MPO (0.66) | MPOXDHCA12CA2CA9 | |
| SCHEMBL2730975 | 0.68 | MPO (1.00) | MPOXDHCA12CA2CA9 | |
| SCHEMBL15549239 | 0.66 | MPO (1.00) | MPOXDHCA12CA2CA9 | |
| SCHEMBL2731131 | 0.64 | XDH (0.64) | MPOXDHKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225612-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225612-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | NOX4, NOX5, NQO2 | MPO 10/4885XDH 11/4885CA12 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.